- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03050905
Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B
An Open-Label, Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus (HCV) Infection Genotype 2K/1B- NINJA Study
HCV infection is one of the most prevalent etiologies for liver cirrhosis and hepatocellular carcinoma. HCV is highly heterogeneous, with seven confirmed major genotypes. Each genotype displays a different geographic distribution.
Since different HCV genotypes react differently on available antiviral therapies, the correct identification of HCV genotype serves as a marker of responsiveness and an indicator for duration of treatment.
The recombinant HCV genotype 2k/1b was first described in Saint Petersburg in 2002.
A sequencing strategy led to the detection of HCV genotype 2k/1b. However, clinical laboratories often use the VERSANT HCV Genotype 2.0 Assay for routine HCV genotyping. This assay may potentially misclassify these HCV strains as genotype 2a/2c. Based on these findings, the number of patients with 2k/1b may be underestimated.
AbbVie's IFN-free regimen for the treatment of chronic HCV genotype 1b infection includes 3 DAAs with distinct mechanisms of action and non-overlapping resistance pattern to target HCV proteins essential for viral replication. The high efficacy of the 3D regimen was proven in registration clinical trials and RW for 1b population.
3D regimen has not been evaluated for patients with HCV genotype 2K/1B. Primary Objective
• Evaluate the efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir (3D) in an interferon-free treatment regimen as assessed by SVR in adult patients with HCV 2k/1b.
Study Design:
.The study will include 1 group. Patients with HCV GT 2k1b will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir. Subjects will be assessed for antiviral response, clinical outcomes, patient reported adverse events and presence and emergence of resistance associated variants. Subjects will be followed for up to 12 weeks of treatment and extra 24 weeks of follow up. Scheduled visits will include: physician assessment and blood tests including HCV resistance mutations.
Study Overview
Detailed Description
Study Procedures:
Initial screening period:
HCV GT2K/1B -infected subjects who will be meeting eligibility criteria, will provide written informed consent, perform baseline RAS testing and will be enrolled to the study.
Baseline period:
On day 0, all patients will be assessed by a general physical examination, blood and urine tests including HCV resistance mutations (elaborated in the budget file), Fibroscan or SHEAR WAVE Elastography and abdominal ultrasound. After the initial assessment all included will be allocated for treatment.
Study configuration:
The study will include 1 group of patients infected GT 2k1b. Patients will be treated according to label recommendation for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir. Scheduled visits will take place in 0, 4, 12 and 24 weeks for all patients.
All visits will include: physician assessment and blood tests as elaborated in the Study Flowchart. Subjects will be assessed for antiviral response, clinical outcomes, patient reported adverse events and presence and emergence of resistance associated variants.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Afula, Israel
- HaEmek Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years or older
- Male and female
- HCV Genotype 2K/1B (P/R experienced or naïve; non-cirrhotic/ Comp. cirrhotic CP-A 5)
- Capable to provide informed consent
Exclusion Criteria:
- Could not remain in the study for 36 weeks
- Co-infected with human immunodeficiency virus (HIV) or HBV
- Severe renal impairment (calculated creatinine clearance <30 mL/min )
- Evidence of hepatocellular carcinoma (HCC)
- Severe concurrent disease
- Pregnant, lactating, expecting to conceive or donate eggs or male participant with pregnant female partner
- DAA treatment experienced
- History of drug or alcohol abuse within 6 months prior enrolment - positive result of a urine drug screen at the screening visit and a positive result on the alcohol consumption questioner.
- Evidence or history of chronic liver disease not caused by HCV Participants currently enrolled in an HCV-related research protocol OR currently receiving HCV treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
The study will include 1 group.
Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks.
All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (VEKIRAX) and Dasabuvir (EXVIERA).
|
Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (Viekirax). Study Regimen: ombitasvir+paritaprevir+ritonavir (25+150+100mg once daily)
Other Names:
Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Dasabuvir (Exviera). Study Regimen: dasabuvir (250 mg twice daily)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The percentage of patients achieving SVR12 (single last HCV RNA <12 IU/mL 12 weeks after the last actual dose of the ABBVIE regimen)
Time Frame: 12 weeks post treatment
|
12 weeks post treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety: absolute and relative numbers of discontinuations, AE and SAEs (Number of Participants With Adverse Events That Are Related to Treatment).
Time Frame: 36 weeks
|
36 weeks
|
Resistance Associated Substitute (RAS): The percentage of patients with the presence of RAS's- at baseline and at post-treatment weak 12.
Time Frame: 12 weeks post treatment
|
12 weeks post treatment
|
Time of virologic failure using population sequencing; SVR12 rate
Time Frame: 36 weeks
|
36 weeks
|
Time of virologic failure using population sequencing; presence of BL RAS's.
Time Frame: 36 weeks
|
36 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Hepatitis, Chronic
- Hepatitis
- Hepatitis C
- Hepatitis C, Chronic
- Coinfection
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Ritonavir
Other Study ID Numbers
- NINJA Study - 11227
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HCV Coinfection
-
Assiut UniversitySohag University; South Valley UniversityCompletedHCV CoinfectionEgypt
-
Sherief Abd-ElsalamRecruiting
-
Yale UniversityNational Institute on Drug Abuse (NIDA); NYU Langone Health; Kenya National AIDS...Completed
-
Hospital de Clinicas de Porto AlegreUniversidade Federal de Santa MariaCompletedHIV Infection | HCV Coinfection
-
Fundacion para la Investigacion Biomedica del Hospital...Instituto de Salud Carlos IIICompletedHIV Infection | HCV CoinfectionSpain
-
Hoffmann-La RocheTerminated
-
Juan MacíasSpanish National Health SystemUnknownHIV Infection | HCV CoinfectionSpain
-
Johns Hopkins UniversityCompletedHIV | Liver Disease | HCV CoinfectionUnited States
-
Corporacion Parc TauliCompletedHCV Coinfection | HCV Infection
-
Fundacion SEIMC-GESIDAViiV HealthcareCompletedHCV Coinfection | Chronic HIV InfectionSpain